Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis

Breast Cancer Research and Treatment

Volumn 172, Issue 2, 2018, Pages 247-263

  Green, Angela K ^a   Aviki, Emeline M ^a   Matsoukas, Konstantina ^a   Patil, Sujata ^a   Korenstein, Deborah ^a   Blinder, Victoria ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy administration; Delays; Disparities; Race; Relative dose intensity

Indexed keywords

ANTINEOPLASTIC AGENT;

BLACK PERSON; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CAUCASIAN; DRUG WITHDRAWAL; HEALTH DISPARITY; HUMAN; META ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; REVIEW; SYSTEMATIC REVIEW; THERAPY DELAY; ADJUVANT CHEMOTHERAPY; AFRICAN AMERICAN; ANCESTRY GROUP; BREAST TUMOR; FEMALE; PATHOLOGY; PROCEDURES;

AFRICAN AMERICANS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONTINENTAL POPULATION GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; NEOPLASM STAGING;

EID: 85051291388     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-018-4909-5     Document Type: Review

References (33)

1. Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM (2013) Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer 13:240
2. Biagi JJRM, King WD, Kong W, Booth CM, Mackillop WJ (2011) The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): a systematic review and meta-analysis. J Clin Oncol 29(15):1128–1128
3. Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH (2016) Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2(3):322–329
4. Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2(11):1281–1288
5. Wood WC, Budman DR, Korzun AH et al (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330(18):1253–1259
6. Budman DR, Berry DA, Cirrincione CT et al (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90(16):1205–1211
7. Pronzato P, Campora E, Amoroso D et al (1989) Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 12(6):481–485
8. Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4(8):1162–1170
9. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332(14):901–906
10. Wheeler SB, Reeder-Hayes KE, Carey LA (2013) Disparities in breast cancer treatment and outcomes: Biological, social, and health system determinants and opportunities for research. Oncologist 18(9):986–993
11. Hershman D, Weinberg M, Rosner Z et al (2003) Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 95(20):1545–1548
12. Bain BJ (1996) Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol 49(8):664–666
13. Penner LA, Eggly S, Griggs JJ, Underwood W III, Orom H, Albrecht TL (2012) Life-threatening disparities: the treatment of black and white cancer patients. J Soc Issues 68(2):328–357
14. Green AR, Carney DR, Pallin DJ et al (2007) Implicit bias among physicians and its prediction of thrombolysis decisions for black and white patients. J Genet Intern Med 22(9):1231–1238
15. O’Malley AS, Sheppard VB, Schwartz M, Mandelblatt J (2004) The role of trust in use of preventive services among low-income African-American women. Prev Med 38(6):777–785
16. Griggs JJ, Liu Y, Sorbero ME, Jagielski CH, Maly RC (2014) Adjuvant chemotherapy dosing in low-income women: the impact of Hispanic ethnicity and patient self-efficacy. Br Cancer Res Treat 144(3):665–672
17. Griggs JJ, Culakova E, Sorbero ME et al (2007) Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol 25(3):277–284
18. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW (2003) Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat 81(1):21–31
19. Hershman DL, Unger JM, Barlow WE et al (2009) Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of southwest oncology studies S8814/S8897. J Clin Oncol 27(13):2157–2162
20. Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21(24):4524–4531
21. Hershman D, McBride R, Jacobson JS et al (2005) Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23(27):6639–6646
22. Simon MS, Lamerato L, Krajenta R et al (2012) Racial differences in the use of adjuvant chemotherapy for breast cancer in a large urban integrated health system. Int J Br cancer 2012:453985
23. McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED (2012) Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 30(36):4493–4500
24. Gwyn K, Bondy ML, Cohen DS et al (2004) Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer 100(8):1595–1604
25. Gorin SS, Heck JE, Cheng B, Smith SJ (2006) Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med 166(20):2244–2252
26. Vandergrift JL, Niland JC, Theriault RL et al (2013) Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst 105(2):104–112
27. Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99(3):313–321
28. Fedewa SA, Ward EM, Stewart AK, Edge SB (2010) Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004–2006. J Clin Oncol 28(27):4135–4141
29. Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL (2013) Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol 30(1):419
30. de Gagliato M, Gonzalez-Angulo AM, Lei X et al (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735–744
31. Reyes SA, King TA, Fei K, Franco R, Bickell NA (2016) Factors affecting the completion of adjuvant chemotherapy in early-stage breast cancer. Ann Surg Oncol 23(5):1537–1542
32. Yi M, Mittendorf EA, Cormier JN et al (2011) Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 29(35):4654–4661
33. Jemal A, Robbins AS, Lin CC et al (2018) Factors that contributed to black-white disparities in survival among nonelderly women with breast cancer between 2004 and 2013. J Clin Oncol 36(1):14–24